Back to results

Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy

Primary Purpose

Central Serous Chorioretinopathy

Status

Unknown status

Phase

Phase 2

Locations

Mexico

Study Type

Interventional

Intervention

Intravitreal injection of Bevacizumab

About this trial

This is an interventional treatment trial for Central Serous Chorioretinopathy

Eligibility Criteria

20 Years - 50 Years (Adult)All Sexes

Inclusion Criteria

Any visual acuity.
Central serous chorioretinopathy

Sites / Locations

Asociacion para Evitar la Ceguera en MexicoRecruiting

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

NCT ID

NCT00418431

First Posted

January 3, 2007

Last Updated

January 3, 2007

Sponsor

Asociación para Evitar la Ceguera en México

1. Study Identification

Unique Protocol Identification Number

NCT00418431

Brief Title

Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy

Study Type

Interventional

2. Study Status

Record Verification Date

June 2006

Overall Recruitment Status

Unknown status

Study Start Date

April 2006 (undefined)

Primary Completion Date

undefined (undefined)

Study Completion Date

August 2006 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor

Asociación para Evitar la Ceguera en México

4. Oversight

5. Study Description

Brief Summary

Central serous chorioretinopathy (CSC) has been known since it was first described by Von Graefe and termed "idiopathic detachment of the macula" in 1866, is a well-characterized disorder leading to serous neurosensory elevation of the central macula. The acute form of the disease is associated with focal leakage at the level of the retinal pigment epithelium (RPE) demonstrated with fluorescein angiography (FA). The disorder is self-limited in the majority of patients, who also regain excellent vision. Occasionally, the neurosensory detachment persists and leads to pigment epithelial and photoreceptor damage with visual impairment. The purpose of this clinical study is report the use of intravitreal bevacizumab is a new option in the treatment of the chronic or recurrent CSC.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Central Serous Chorioretinopathy

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 2, Phase 3

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

Non-Randomized

8. Arms, Groups, and Interventions

Intervention Type

Drug

Intervention Name(s)

Intravitreal injection of Bevacizumab

10. Eligibility

Sex

All

Minimum Age & Unit of Time

20 Years

Maximum Age & Unit of Time

50 Years

Eligibility Criteria

Inclusion Criteria Any visual acuity. Central serous chorioretinopathy

Central Contact Person:

First Name & Middle Initial & Last Name or Official Title & Degree

Mitzy E Torres Soriano, MD

Phone

525510841400

Ext

1172

retinamex@yahoo.com

First Name & Middle Initial & Last Name or Official Title & Degree

Hugo Quiroz-Mercado, MD

Phone

525510841400

Ext

1171

hugoquiroz@yahoo.com

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Mitzy E Torres Soriano, MD

Organizational Affiliation

Asociación para Evitar la Ceguera en México

Official's Role

Principal Investigator

Facility Information:

Facility Name

Asociacion para Evitar la Ceguera en Mexico

City

Mexico DF

State/Province

ZIP/Postal Code

04030

Country

Mexico

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Mitzy E Torres Soriano, MD

Phone

5255510841400

Ext

1171

mitzytorres@yahoo.com

First Name & Middle Initial & Last Name & Degree

Maura Abraham, MD

First Name & Middle Initial & Last Name & Degree

Orlando Ustariz, MD

First Name & Middle Initial & Last Name & Degree

Gerardo Garcia Aguirre

First Name & Middle Initial & Last Name & Degree

Veronica Kon-Jara, MD

First Name & Middle Initial & Last Name & Degree

Hugo Quiroz-Mercado, MD

First Name & Middle Initial & Last Name & Degree

Jose L Guerrero, MD

12. IPD Sharing Statement

Learn more about this trial

Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy

We'll reach out to this number within 24 hrs